FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 	_	_				_	-				-
			W	las	shin	gto	n,	D	C.	2054	19

Washington,	$D \subset$	205/19
wasiiiigton,	D.C.	20549

wasnington, D.C.	20549

OMB APPROVAL									
OMB Number: 3235-0362									
Estimated average burden									

1.0

hours per response:

	to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
\Box	Form 3 Holdings Reported.

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL **OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	sactions Reported.		pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940			()		
1. Name and Add KAKKIS E		g Person*	2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE]		tionship of Reporting Po all applicable)	erson(s) to Issuer		
KAKKIS E	WIIL D			X	Director	10% Owner		
(Last) (First) (Middle)			Statement for Issuer's Fiscal Year Ended (Month/Day/Year)	X	Officer (give title below)	Other (specify below)		
C/O ULTRAGENYX PHARMACEUTICAL INC.			12/31/2020	President & CEO				
60 LEVERON	NI COURT							
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	ridual or Joint/Group Fili	ng (Check Applicable		
NOVATO	CA	94949		X	Form filed by One Re	porting Person		
				Form filed by More than One Reporting Person				
(City)	(State)	(Zip)						
		Table I. Nan Daviss	tive Conveition Associated Dispersed of an Banas	C: -: - II.	. O			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Ac Of (D) (Instr. 3,) or Disposed	5. Amount of Securities Beneficially Owned at end of	6. Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial Ownership		
		(MOIIIII/Day/Teal)	8)	Amount	(A) or (D)	Price	Issuer's Fiscal Year (Instr. 3 and 4)	Indirect (I) (Instr. 4)	(Instr. 4)		
Common Stock	05/22/2020		G	100,000	D	\$0.00	2,349,741	I	By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009		
Common Stock	11/19/2020		G	10,000	D	\$0.00	2,349,741	I	By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009		
Common Stock	05/27/2020		G	40,422	D	\$0.00	578,941	D			
Common Stock	11/27/2020		G	31,248	D	\$0.00	578,941 ⁽¹⁾	D			

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	of I		6. Date Exerc Expiration Da (Month/Day/\)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Remarks:

/s/ Karah Parschauer, attorney-02/03/2021 in-fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).